Unibest
← Back to patent-cliff list

HE-009

Tier C — Watch / trade

HE-009

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:S1PR1

Indications (approved):Systemic lupus erythematosus

Regional status

US
-
EU
-
China
Phase II
2025-11-25
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of HE-009?

Approved indications include: Systemic lupus erythematosus.

When does the HE-009 patent expire?

No public expiry year is available for HE-009 yet; this page updates once verified.

How do I get a quote for HE-009 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-30